Cyclic peptide radiotracers, labeled precursors, and applications targeting tumor HER2
By designing cyclic peptide radiotracers that target tumor HER2, the spatial heterogeneity and dynamic monitoring challenges of HER2 detection have been solved, enabling precise localization of tumor HER2 and efficacy evaluation. This approach is applicable to the diagnosis and treatment of various HER2-overexpressing tumors.
Patent Information
- Application Number
- CN202610721301.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2026-05-25
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2046-05-25
AI Technical Summary
In existing technologies, HER2-targeted detection suffers from spatial heterogeneity, lack of dynamic monitoring, and invasive limitations. In particular, in tumors such as lung cancer, existing probes exhibit high physiological uptake in the liver and kidneys, leading to reduced imaging contrast and masking of liver metastases, thus limiting their clinical application value.
A cyclic peptide radiotracer targeting tumor HER2 and its labeled precursor were developed. An ABC structure was designed, where A is a chelating agent, B is a linker arm, and C is a cyclic peptide compound. A disulfide cyclization structure was formed using a cyclic peptide compound with the amino acid sequence CKIFGSLAFC, and then chelated with a 68Ga nuclide to prepare three cyclic peptide radiotracers: [68Ga]Ga-TZY-2601, [68Ga]Ga-TZY-2602, and [68Ga]Ga-TZY-2603.
It achieves specific binding to tumor HER2 protein, has a long tumor retention time, is easy to synthesize, and can accurately locate HER2-positive tumors through PET/CT imaging. It is suitable for early diagnosis and efficacy evaluation of gastric cancer, breast cancer, colon cancer, lung cancer and other HER2-high expression tumors.
Smart Images

Figure CN122251641B_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of biomedical technology, specifically to a cyclic peptide radiotracer, labeled precursor, and application targeting tumor HER2. Background Technology
[0002] The human epidermal growth factor receptor (HER) family mainly includes four members: HER1, HER2, HER3, and HER4. All are located on the cell membrane surface and respond to extracellular signals such as growth factors, thereby activating downstream signaling pathways and regulating core life activities such as cell proliferation, differentiation, and survival. Among them, HER2 is a clinically valuable tumor biomarker, often exhibiting abnormally high expression in various malignant tumors, including breast cancer, thus becoming a core target in the field of tumor diagnosis and treatment. At the molecular level, HER2 primarily activates key signaling pathways such as Ras / Raf / MAPK and PI3K / Akt through its tyrosine kinase activity, directly regulating cell proliferation and survival. Abnormal activation of HER2 enhances the invasive and metastatic abilities of tumor cells and inhibits apoptosis, thereby driving malignant tumor progression. In clinical diagnosis and treatment, targeted therapy against HER2 has become a core strategy for improving the prognosis of HER2-positive breast cancer patients, with mainstream drugs including monoclonal antibodies, tyrosine kinase inhibitors (TKIs), and antibody-drug conjugates (ADCs). Conversely, HER2-negative patients with extremely low expression cannot benefit from the aforementioned targeted therapies, and clinical strategies must be adopted based on their tumor biology characteristics. For example, the growth of HR-positive / HER2-negative breast cancer is highly dependent on estrogen receptor signaling, and its core treatment is endocrine therapy, which inhibits tumor growth by lowering estrogen levels or blocking estrogen binding to its receptor. Numerous studies have confirmed that HER2 overexpression (IHC 3+ or FISH-detected gene amplification) is significantly associated with enhanced invasive and metastatic capabilities of various malignant tumors, resistance to targeted therapies, and shortened overall survival. Therefore, developing technologies that can quantitatively assess HER2 expression is of crucial clinical value for achieving precise molecular subtyping of tumors, developing individualized treatment plans, and stratifying prognostic risks.
[0003] Currently, routine HER2 testing in clinical practice still primarily relies on tissue biopsy, but this technique has inherent limitations. Firstly, spatial heterogeneity: HER2 expression in tumor tissue exhibits significant spatial heterogeneity, making it difficult to reflect the full picture of the lesion from a single biopsy, easily leading to detection bias. Secondly, inability to dynamically monitor: Treatment can induce downregulation of HER2 expression (with an incidence rate as high as 29.5%), which biopsy cannot track in real time. Thirdly, invasiveness: Biopsy is an invasive procedure with certain risks, making it unsuitable for long-term follow-up requiring multiple assessments. The rapid development of molecular imaging technology has provided innovative solutions to overcome these bottlenecks. Among them, HER2-targeted molecular imaging technology based on positron emission tomography (PET), using radiolabeled specific probes (such as antibodies, nanobodies, peptides, etc.), can achieve whole-body, real-time, three-dimensional, and quantitative visualization of HER2 expression, effectively compensating for the shortcomings of traditional biopsies. For example, 68 Ga-labeled Affibody molecular probe ([ 68 In HER2-positive breast cancer animal models, Ga-ABY-025 has demonstrated excellent tumor targeting and rapid blood clearance. However, extending the application of this probe to other tumors such as lung cancer still faces significant challenges. The probe exhibits high physiological uptake in the liver and kidneys, which not only creates strong background signal interference, reducing imaging contrast and clarity, but may also mask the true signal of liver metastases, thus severely limiting the clinical application value of this technology in tumor staging, efficacy assessment, and metastasis monitoring. Summary of the Invention
[0004] The purpose of this invention is to at least solve one of the technical problems existing in the prior art, and to provide a cyclic peptide radiotracer, a labeling precursor, and an application for targeting tumor HER2. Specifically, it relates to a method for preparing a cyclic peptide radiotracer targeting tumor HER2 and its labeling precursor, as well as its application. The cyclic peptide radiotracer targeting HER2 of this invention has good in vivo stability, good specificity for binding to tumor HER2 protein, long tumor retention time, and is easy to synthesize.
[0005] The technical solution of the present invention is as follows: In a first aspect, the present invention provides a labeled precursor of a cyclic peptide radiotracer targeting tumor HER2, the labeled precursor having an ABC structure, wherein A is a chelating agent, B is a linker arm, and C is a cyclic peptide compound, one end of the linker arm being connected to the chelating agent and the other end being connected to the cyclic peptide compound; The amino acid sequence of the cyclic peptide compound is shown in SEQ ID NO: 1, and the cysteine at position 1 and position 10 form a cyclic structure through a disulfide bond.
[0006] SEQ ID NO: 1: CKIFGSLAFC.
[0007] Preferably, the cyclic peptide compound is selected from any one of (1)-(3) below: (1) The cysteine residues at the C-terminus and N-terminus of the cyclic peptide compound are both L-type; (2) The cysteine at the C-terminus of the cyclic peptide compound is of type L and the cysteine at the N-terminus is of type D; (3) The cysteine at the C-terminus of the cyclic peptide compound is of type D and the cysteine at the N-terminus is of type L.
[0008] Preferably, one end of the linker arm is an amino group and the other end is a carboxyl group, and the amino end of the linker arm is connected to the chelating agent, while the carboxyl end of the linker arm is connected to the amino group of the N-terminal cysteine of the cyclic peptide compound. The connecting arm is selected from one of the following structural formulas: , , , , or ; Where n is an integer in the range of 1 to 10.
[0009] More preferably, the structural formula of the connecting arm is selected from... Where n is an integer in the range of 1 to 5.
[0010] Preferably, the chelating agent is selected from 1, 4, 7, 10. Tetraazacyclododecane 1,4,7,10 Tetraacetic acid (DOTA), 1,4,7 Triazacyclononane N,N',N'' Triacetic acid (NOTA), 4,7,10 3(2) amino 2 (Oxyethyl) 1,4,7,10 Tetraazacyclododecane 1 Acetic acid (DOTAM), 2 (4,7,10 Tri(carboxymethyl) 1,4,7,10 Tetraazacyclododecane 1 Dota glutaric acid (DOTAGA) or 2 (4,7 Double (2) (carboxyethyl) 1,4,7 Triazoline 1 It is one of the following: glutaric acid (NOTAGA).
[0011] Preferably, the present invention provides a labeled precursor of a cyclic peptide radiotracer targeting tumor HER2, wherein the labeled precursor has an ABC structure, wherein A is a chelating agent, B is a linker arm, and C is a cyclic peptide compound; the amino side of the linker arm is connected to the chelating agent, and the carboxyl side of the linker arm is connected to the N-terminal cysteine amino side of the cyclic peptide compound; the cyclic peptide compound is a cyclic decapeptide with an intramolecular disulfide ring, and its amino acid sequence is cyclo(1,10)[CKIFGSLAFC] (SEQ ID NO: 1). NO: 1), where cyclo indicates a cyclic structure, (1,10) indicates the position of the cyclization connection, that is, the first amino acid (cysteine Cys) and the tenth amino acid (cysteine Cys) form a cyclization, [CKIFGSLAFC] is the linear sequence of the cyclic peptide compound, namely Cys-Lys-Ile-Phe-Gly-Ser-Leu-Ala-Phe-Cys, and the two cysteines (Cys) involved in the cyclization form a cyclization structure through disulfide bonds; More preferably, the chelating agent is selected from 1, 4, 7, 10. Tetraazacyclododecane 1,4,7,10 Tetraacetic acid (DOTA).
[0012] Secondly, the present invention provides a method for preparing the aforementioned labeled precursor, comprising the following steps: S1. Synthesize the cyclic peptide compound; S2. The cyclic peptide compound is coupled with a linker and a chelating agent to obtain a crude product of the labeled precursor. S3. The crude product is purified to obtain the labeled precursor.
[0013] Preferably, the method for synthesizing the cyclic peptide compound in S1 includes: synthesizing a linear polypeptide having the same amino acid sequence as the cyclic peptide compound, and then oxidizing it into a ring by introducing air onto a solid support to obtain the cyclic peptide compound.
[0014] The purification reagent described in S3 is a mixture of diethyl ether and n-hexane, and the volume ratio of diethyl ether to n-hexane is 1:1.
[0015] Thirdly, the present invention provides a cyclic peptide radiotracer targeting tumor HER2, wherein the cyclic peptide radiotracer comprises a radionuclide and the aforementioned labeled precursor, and the structure of the cyclic peptide radiotracer is DABC, wherein D is selected from the radionuclide. 68 Ga.
[0016] Preferably, the cyclic peptide radiotracer is obtained by chelating the nuclide with the labeled precursor.
[0017] Preferably, the preparation method includes the following steps: The labeling precursor is dissolved in a buffer solution to obtain a labeling precursor solution; wherein the buffer solution is selected from at least one of sodium acetate, water, ethanol, phosphate buffer solution and dimethyl sulfoxide, and the pH value of the buffer solution is 4.0 to 6.0; The labeled precursor solution was mixed with a radionuclide solution and incubated to obtain a cyclic peptide radiotracer; wherein the radionuclide solution was selected from... 68 The GaCl3 solution was used for incubation under the following conditions: incubation at 80℃~100℃ for 5min~20min.
[0018] Fourthly, the present invention provides the application of the labeled precursor in the preparation of cyclic peptide radiotracers targeting tumor HER2.
[0019] Fifthly, the present invention provides the use of the labeled precursor or the cyclic peptide radiotracer in any one of the following (1)-(3): (1) Preparation of diagnostic products and / or therapeutic drugs labeled with diagnostic radionuclides; (2) Preparation of therapeutic drugs labeled with therapeutic radionuclides; (3) Prepare diagnostic products and / or therapeutic drugs for tumors with high HER2 expression; The diagnostic products include diagnostic reagents or diagnostic drugs.
[0020] Preferably, the HER2-overexpressing tumors include gastric cancer, breast cancer, colon cancer, lung cancer, pancreatic cancer, and other tumors that can affect HER2 expression status.
[0021] This invention has at least one of the following beneficial effects: This invention addresses the structural characteristics of the tumor-targeting HER2 cyclic peptide molecule cyclo(1,10)[CKIFGSLAFC]. Without affecting its binding site to the target protein, the side chain portion is structurally modified to introduce binding sites that can chelate positron-emitting radionuclides. By altering the chiral conformation of the two cysteine residues in the cyclic peptide's core, three novel tumor-targeting HER2 cyclic peptide marker precursors are constructed: TZY-2601, TZY-2602, and TZY-2603. These three cyclic peptide marker precursors exhibit good stability, are easy to synthesize, and can be chelated with radionuclides. 68 Ga labeling yielded three cyclic peptide radiotracers: [ 68 Ga]Ga-TZY-2601、[ 68 Ga]Ga-TZY-2602 and [ 68 Ga]Ga-TZY-2603. The three cyclic peptide radiotracers described herein can specifically bind to the HER2 protein in tumor tissue, enabling precise localization of HER2-positive tumors via PET / CT imaging, thereby achieving early tumor diagnosis and efficacy assessment. Therefore, the cyclic peptide radiotracers prepared in this invention have significant value in the integrated clinical application of tumor-targeted radiopharmaceutical diagnosis and treatment. Attached Figure Description
[0022] Figure 1 The image shows the characterization of the labeled precursor TZY-2601; where (A) is the mass spectrum, (B) is the high-performance liquid chromatography (HPLC) chromatogram, and (C) is the radioactive tracer. 68 Radioactive high-performance liquid chromatogram of Ga]Ga-TZY-2601; Figure 2 The image shows the characterization of the labeled precursor TZY-2602; where (A) is the mass spectrum, (B) is the high-performance liquid chromatography (HPLC) chromatogram, and (C) is the radioactive tracer. 68 Radioactive high-performance liquid chromatogram of Ga]Ga-TZY-2602; Figure 3 The image shows the characterization of the precursor TZY-2603; where (A) is the mass spectrum, (B) is the high-performance liquid chromatography (HPLC) chromatogram, and (C) is the radioactive tracer. 68 Radioactive high-performance liquid chromatogram of Ga]Ga-TZY-2603; Figure 4 for[ 68 Ga]Ga-TZY-2601、[ 68 Ga]Ga-TZY-2602 and [ 68In vitro stability study of Ga-TZY-2603 in PBS buffer and mouse serum; where (A) in the figure is [ 68 Stability study of Ga-TZY-2601 in PBS buffer solution, (B) in the figure is [ 68 Stability study of Ga-TZY-2601 in mouse serum, (C) in the figure represents [Ga]Ga-TZY-2601. 68 Stability study of Ga-TZY-2602 in PBS buffer solution, (D) in the figure is [ 68 Stability study of Ga-TZY-2602 in mouse serum, (E) in the figure represents [Ga]Ga-TZY-2602. 68 Stability study of Ga-TZY-2603 in PBS buffer solution, with (F) in the figure representing [ 68 Stability study of Ga]Ga-TZY-2603 in mouse serum; Figure 5 for[ 68 Ga]Ga-TZY-2601、[ 68 Ga]Ga-TZY-2602 and [ 68 Results of the specific uptake and binding affinity test of Ga-TZY-2603 with HER2-overexpressing tumor cells in vitro; where (A) in the figure represents the time-cell binding affinity in vitro, and (B) in the figure represents the concentration-cell binding affinity in vitro; Figure 6 for[ 68 Ga]Ga-TZY-2601、[ 68 Ga]Ga-TZY-2602 and [ 68 The results of in vivo PET / CT imaging of Ga]Ga-TZY-2603 in HCC827 tumor-bearing BALB / c mice; where (A) in the figure is the PET / CT imaging of the three tracers in tumor-bearing mice, and (B) in the figure is the uptake value of the three tracers in normal tissue and tumor tissue. Figure 7 for[ 68 Ga]Ga-TZY-2603 and [ 68 Comparative PET / CT imaging study of Ga-DOTA-WC8 in tumor-bearing mice; where (A) in the figure is [ 68 PET / CT imaging of Ga-TZY-2603 in tumor-bearing mice, where (B) in the image represents [Ga-TZY-2603]. 68 PET / CT imaging of Ga]Ga-DOTA-WC8 in tumor-bearing mice, where (C) represents the uptake values of the two tracers in normal and tumor tissues; Figure 8for[ 68 In vitro biodistribution of Ga]Ga-TZY-2603 in HCC827 tumor-bearing mice.
[0023] Figure 9 Synthetic route for the labeled precursor TZY-2601.
[0024] Figure 10 Synthetic route for the labeled precursor TZY-2602.
[0025] Figure 11 Synthetic route for the labeled precursor TZY-2603. Detailed Implementation
[0026] To make the technical problems solved, the technical solutions, and the beneficial effects of this invention clearer, the invention will be further described in detail below with reference to the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.
[0027] The test methods involved in the following embodiments are as follows: The nuclides used in this invention 68 Ga was prepared using a germanium-gallium generator (Jiangsu Huayi), and its radionuclide purity was 98%. Radioactive high-performance liquid chromatography (HPLC) analysis of all radiotracers was performed using an HPLC system (Shimadzu, Japan).
[0028] This invention uses the lung cancer HCC827 cell line as a cell model. The culture medium is DMEM high-glucose medium + 10% fetal bovine serum + 1% penicillin / streptomycin, and the culture conditions are 37 ℃, 5% CO2. Subculturing is performed every three days. The medium is changed every two days.
[0029] All animal experiments in this invention were approved by the Animal Ethics Committee of Nanchang Medical College. All animal experiments adhered to the 3R principle and were conducted under the guidance of the Laboratory Animal Ethics Committee. A tumor-bearing BALB / c mouse model was established by subcutaneous injection of HCC827 cells; each mouse received a unilateral injection of 1 × 10⁻⁶ HCC827 cells into one axilla. 6 One cell was used to construct one tumor per mouse. After 2 weeks, when the tumor tissue grew to approximately 100 mm... 3 -300 mm 3 At that time, mice were given the drug and PET / CT imaging studies were conducted.
[0030] The meanings of the English terms and abbreviations involved in this invention are as follows: Fmoc: 9 Phosphate oxycarbonyl; Resin: resin; DMF: N,N Dimethylformamide; DCM: Dichloromethane; NMP: N Methylpyrrolidone; HCTU: 6 chlorobenzotriazole 1,1,3,3 Tetramethylurea hexafluorophosphate; TFA: Trifluoroacetic acid; DIPEA:N,N Diisopropylethylamine; TIPS: Triisopropylsilane; Boc: tert-butyloxycarbonyl; tBu: tert-butyl; DOTA: 1,4,7,10 Tetraazacyclododecane 1,4,7,10 Tetraacetic acid.
[0031] Example 1 This embodiment provides a cyclic peptide-labeled precursor TZY-2601 targeting tumor HER2 and a radioactive tracer. 68 The synthesis of Ga-TZY-2601 is as follows: Using a Fmoc-based solid-phase peptide synthesis method, a linear peptide CKIFGSLAFC (all cysteines are L-form) with the same amino acid sequence as the cyclic peptide compound cyclo(1,10)[CKIFGSLAFC] was first synthesized. Then, air was bubbled through the peptide onto a solid support to induce cyclization. The peptide was then sequentially coupled with a linker and a chelating agent, followed by deprotection. The crude product was cleaved from the resin and purified by Prep-HPLC to obtain the labeled precursor TZY-2601. The synthetic route is as follows: Figure 9 As shown: The specific operating steps are as follows: (1) Resin swelling: 200 mg of 2-chlorotriphenylmethyl chloride resin (CTC Resin, degree of substitution 0.5 mmol / g) was added to the reaction tube, followed by the addition of DCM (3 mL), and the reaction was carried out under nitrogen for 30 min.
[0032] (2) Deprotection: Discard the solvent, add 3 mL of piperidine / DMF mixed solution (1 / 4, v / v) and react for 5 min. Then discard the solvent and add 3 mL of piperidine / DMF mixed solution (1 / 4, v / v) again and react for 15 min.
[0033] (3) Resin cleaning: Discard the solvent and wash with DMF (3 mL × 2), DCM (3 mL × 2) and DMF (3 mL × 2) in sequence.
[0034] (4) First amino acid linkage: Fmoc-L-Cys-OH (3 eq, 103 mg), HCTU (3 eq, 124 mg) and DIPEA (10 eq, 129 mg) were added to the reaction tube in sequence, and then DMF (3 mL) was added to dissolve them. Nitrogen gas was blown in for 60 min.
[0035] (5) Resin cleaning: Discard the solvent and wash with DMF (3 mL × 2), DCM (3 mL × 2) and DMF (3 mL × 2) in sequence.
[0036] (6) Deprotection: Add 3 mL of piperidine / DMF mixed solution (1 / 4, v / v) and react for 5 min. Then discard the solvent and add 3 mL of piperidine / DMF mixed solution (1 / 4, v / v) again and react for 15 min.
[0037] (7) Resin cleaning: Discard the solvent and wash with DMF (3 mL × 2), DCM (3 mL × 2) and DMF (3 mL × 2) in sequence.
[0038] (8) Second amino acid linkage: Fmoc-Phe-OH (3 eq, 116 mg), HCTU (3 eq, 124 mg) and DIPEA (10 eq, 129 mg) were added to the reaction tube in sequence, and then DMF (3 mL) was added to dissolve them. Nitrogen gas was blown in for 30 min to react.
[0039] Repeat the above steps, sequentially connecting: Fmoc-Ala-OH (93 mg), Fmoc-Leu-OH (106 mg), Fmoc-Ser(tBu)-OH (115 mg), Fmoc-Gly-OH (89 mg), Fmoc-Phe-OH (116 mg), Fmoc-Ile-OH (106 mg), Fmoc-Lys(Boc)-OH (141 mg), and Fmoc-L-Cys-OH (103 mg), with each substance used in an amount of 3 eq.
[0040] (9) Oxidative cyclization: Wash the resin with DCM (2 mL × 3), then add NMP (2 mL), and adjust the pH of the solution to 7.5 with Et3N. The oxidation reaction was carried out at room temperature for 12 hours with air introduced between 9.0 and 9.0.
[0041] (10) Resin cleaning: Discard the solvent and wash with DMF (3 mL × 2), DCM (3 mL × 2) and DMF (3 mL × 2) in sequence.
[0042] (11) Connecting arm coupling: Add Fmoc sequentially to the reaction tube NH-(CH2)5-COOH (3 eq, 102 mg), HCTU (3 eq, 124 mg) and DIPEA (10 eq, 129 mg) were dissolved in DMF (3 mL) and reacted under nitrogen for 30 min.
[0043] (12) Resin cleaning: Discard the solvent and wash with DMF (3 mL × 2), DCM (3 mL × 2) and DMF (3 mL × 2) in sequence.
[0044] (13) Deprotection: Add 3 mL of piperidine / DMF mixed solution (1 / 4, v / v) and react for 5 min. Then discard the solvent and add 3 mL of piperidine / DMF mixed solution (1 / 4, v / v) again and react for 15 min.
[0045] (14) Resin cleaning: Discard the solvent and wash with DMF (3 mL × 2), DCM (3 mL × 2) and DMF (3 mL × 2) in sequence.
[0046] (15) Coupling with chelating agents: Tri-tert-butyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid [DOTA-tri(t-butyl ester)] (3 eq, 172 mg), HCTU (3 eq, 124 mg) and DIPEA (10 eq, 129 mg) were added sequentially to the reaction tube, and then DMF (3 mL) was added to dissolve them. The reaction was carried out under nitrogen for 30 min.
[0047] (16) Resin cleaning: Discard the solvent and wash with DMF (3 mL × 2), DCM (3 mL × 2) and DMF (3 mL × 2) in sequence.
[0048] (17) Peptide shearing: Add 3 mL of shearing solution (TFA / TIPS / H2O = 95 / 2.5 / 2.5, v / v / v) to the reaction tube and place it on a shaker for 2 h.
[0049] (18) Filtration: Add the shearing system to a 1 mL disposable sterile syringe stuffed with cotton and filter. Rinse the resin with an appropriate amount of TFA. Dry the filtrate with nitrogen to obtain crude peptide solid.
[0050] (19) Purification: Add 3 mL of pre-cooled diethyl ether / n-hexane mixture (1 / 1, v / v) to the above crude peptide solid and sonicate for 30 s. Then centrifuge at 1500 rpm for at least 5 min and discard the supernatant. Subsequently, blow the precipitate with nitrogen and freeze dry to obtain a white powdery labeled precursor TZY-2601.
[0051] The mass spectrum and HPLC detection chromatogram of TZY-2601 are shown below. Figure 1 (A) and Figure 1 The structure of (B) in the middle is shown below: (20) Radionuclide labeling: TZY-2601 (20 μg) was dissolved in sodium acetate solution (0.1 mol / L, 100 mL, pH 4.1), and then added 68 A GaCl3 (10 mCi) solution was incubated at 80 °C for 10 min. The solution was diluted with physiological saline and filtered through a 0.2 μm sterile filter membrane to obtain a cyclic peptide radiotracer targeting tumor HER2. 68 Ga]Ga-TZY-2601. Utilizing YMC tria C18 filter column radio HPLC analysis 68 The radiochemical purity of Ga-TZY-2601 was determined under the following analytical conditions: column: X-Bridge C18; mobile phase A: H2O (containing 0.1% TFA); mobile phase B: acetonitrile (containing 0.1% TFA); elution gradient: mobile phase B increased from 10% to 90% within 20 min; flow rate: 1.0 mL / min.
[0052] The cyclic peptide radiotracer prepared in this embodiment [ 68 Ga]Ga-TZY-2601 for Radio HPLC analysis showed the following results: 68 The radiochemical purity of Ga]TZY-2601 is greater than 95% (Table 1), and the retention time is approximately 5.38 min. Figure 1 In the middle (C), the molar activity of the tracer is greater than 74 ± 10 GBq / μmol (Table 1).
[0053] Table 1. 68 Ga]Ga-TZY-2601、[ 68 Ga]Ga-TZY-2602 and [ 68 Quality control results of Ga-TZY-2603 Example 2 This embodiment provides a cyclic peptide-labeled precursor TZY-2602 targeting tumor HER2 and a radioactive tracer. 68 The synthesis method of Ga-TZY-2602 is as follows: Using a Fmoc-based solid-phase peptide synthesis method, a linear peptide CKIFGSLAFC with the same amino acid sequence as the cyclic peptide compound cyclo(1,10)[CKIFGSLAFC] (C-terminal cysteine is L-type and N-terminal cysteine is D-type) was first synthesized. Then, air was bubbled onto a solid support for cyclic oxidation, followed by sequential coupling with a linker and a chelating agent. The protecting group was then removed, and the crude product was cleaved from the resin. Prep-HPLC purification yielded the labeled precursor TZY-2602. The synthetic route is as follows: Figure 10 As shown: The specific operating steps are as follows: (1) Resin swelling: 200 mg of 2-chlorotriphenylmethyl chloride resin (CTC Resin, degree of substitution 0.5 mmol / g) was added to the reaction tube, followed by the addition of DCM (3 mL), and the reaction was carried out under nitrogen for 30 min.
[0054] (2) Deprotection: Discard the solvent, add 3 mL of piperidine / DMF mixed solution (1 / 4, v / v) and react for 5 min. Then discard the solvent and add 3 mL of piperidine / DMF mixed solution (1 / 4, v / v) again and react for 15 min.
[0055] (3) Resin cleaning: Discard the solvent and wash with DMF (3 mL × 2), DCM (3 mL × 2) and DMF (3 mL × 2) in sequence.
[0056] (4) First amino acid linkage: Fmoc-L-Cys-OH (3 eq, 103 mg), HCTU (3 eq, 124 mg) and DIPEA (10 eq, 129 mg) were added to the reaction tube in sequence, and then DMF (3 mL) was added to dissolve them. Nitrogen gas was blown in for 60 min.
[0057] (5) Resin cleaning: Discard the solvent and wash with DMF (3 mL × 2), DCM (3 mL × 2) and DMF (3 mL × 2) in sequence.
[0058] (6) Deprotection: Add 3 mL of piperidine / DMF mixed solution (1 / 4, v / v) and react for 5 min. Then discard the solvent and add 3 mL of piperidine / DMF mixed solution (1 / 4, v / v) again and react for 15 min.
[0059] (7) Resin cleaning: Discard the solvent and wash with DMF (3 mL × 2), DCM (3 mL × 2) and DMF (3 mL × 2) in sequence.
[0060] (8) Second amino acid linkage: Fmoc-Phe-OH (3 eq, 116 mg), HCTU (3 eq, 124 mg) and DIPEA (10 eq, 129 mg) were added to the reaction tube in sequence, and then DMF (3 mL) was added to dissolve them. Nitrogen gas was blown in for 30 min to react.
[0061] Repeat the above steps, sequentially connecting: Fmoc-Ala-OH (93 mg), Fmoc-Leu-OH (106 mg), Fmoc-Ser(tBu)-OH (115 mg), Fmoc-Gly-OH (89 mg), Fmoc-Phe-OH (116 mg), Fmoc-Ile-OH (106 mg), Fmoc-Lys(Boc)-OH (141 mg), and Fmoc-D-Cys-OH (103 mg), with each substance used in an amount of 3 eq.
[0062] (9) Oxidative cyclization: Wash the resin with DCM (2 mL × 3), then add NMP (2 mL), and adjust the pH of the solution to 7.5 with Et3N. The oxidation reaction was carried out at room temperature for 12 hours with air introduced between 9.0 and 9.0.
[0063] (10) Resin cleaning: Discard the solvent and wash with DMF (3 mL × 2), DCM (3 mL × 2) and DMF (3 mL × 2) in sequence.
[0064] (11) Connecting arm coupling: Add Fmoc sequentially to the reaction tube NH-(CH2)5-COOH (3 eq, 102 mg), HCTU (3 eq, 124 mg) and DIPEA (10 eq, 129 mg) were dissolved in DMF (3 mL) and reacted under nitrogen for 30 min.
[0065] (12) Resin cleaning: Discard the solvent and wash with DMF (3 mL × 2), DCM (3 mL × 2) and DMF (3 mL × 2) in sequence.
[0066] (13) Deprotection: Add 3 mL of piperidine / DMF mixed solution (1 / 4, v / v) and react for 5 min. Then discard the solvent and add 3 mL of piperidine / DMF mixed solution (1 / 4, v / v) again and react for 15 min.
[0067] (14) Resin cleaning: Discard the solvent and wash with DMF (3 mL × 2), DCM (3 mL × 2) and DMF (3 mL × 2) in sequence.
[0068] (15) Coupling with chelating agents: Tri-tert-butyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid [DOTA-tri(t-butyl ester)] (3 eq, 172 mg), HCTU (3 eq, 124 mg) and DIPEA (10 eq, 129 mg) were added sequentially to the reaction tube, and then DMF (3 mL) was added to dissolve them. The reaction was carried out under nitrogen for 30 min.
[0069] (16) Resin cleaning: Discard the solvent and wash with DMF (3 mL × 2), DCM (3 mL × 2) and DMF (3 mL × 2) in sequence.
[0070] (17) Peptide shearing: Add 3 mL of shearing solution (TFA / TIPS / H2O = 95 / 2.5 / 2.5, v / v / v) to the reaction tube and place it on a shaker for 2 h.
[0071] (18) Filtration: Add the shearing system to a 1 mL disposable sterile syringe stuffed with cotton and filter. Rinse the resin with an appropriate amount of TFA. Dry the filtrate with nitrogen to obtain crude peptide solid.
[0072] (19) Purification: Add 3 mL of pre-cooled diethyl ether / n-hexane mixture (1 / 1, v / v) to the above crude peptide solid and sonicate for 30 s. Then centrifuge at 1500 rpm for at least 5 min and discard the supernatant. Subsequently, blow the precipitate with nitrogen and freeze dry to obtain white powdered labeled precursor TZY-2602.
[0073] The mass spectrum and HPLC detection chromatogram of TZY-2602 are shown below. Figure 2 (A) and Figure 2 The structure of (B) in the middle is shown below: (20) Radionuclide labeling: TZY-2602 (20 μg) was dissolved in sodium acetate solution (0.1 mol / L, 100 mL, pH 4.1), and then added 68 A GaCl3 (10 mCi) solution was incubated at 80 °C for 10 min. The solution was diluted with physiological saline and filtered through a 0.2 μm sterile filter membrane to obtain a cyclic peptide radiotracer targeting tumor HER2. 68 Ga]Ga-TZY-2602. Utilizing YMC tria C18 filter column radio HPLC analysis 68 The radiochemical purity of Ga-TZY-2602 was determined under the following analytical conditions: column: X-Bridge C18; mobile phase A: H2O (containing 0.1% TFA); mobile phase B: acetonitrile (containing 0.1% TFA); elution gradient: mobile phase B increased from 10% to 90% within 20 min; flow rate: 1.0 mL / min.
[0074] The cyclic peptide radiotracer prepared in this embodiment [ 68 Ga]Ga-TZY-2602 for Radio HPLC analysis showed the following results: 68 The radiochemical purity of Ga]TZY-2602 is greater than 95% (Table 1), and the retention time is approximately 5.80 min. Figure 2 In the middle (C), the molar activity of the tracer is greater than 74 ± 10 GBq / μmol (Table 1).
[0075] Example 3 This embodiment provides a cyclic peptide-labeled precursor TZY-2603 targeting tumor HER2 and a radioactive tracer. 68 The synthesis method of Ga-TZY-2603 is as follows: Using a Fmoc-based solid-phase peptide synthesis method, a linear peptide CKIFGSLAFC with the same amino acid sequence as the cyclic peptide compound cyclo(1,10)[CKIFGSLAFC] (C-terminal cysteine is D-type, N-terminal cysteine is L-type) was first synthesized. Then, air was bubbled onto a solid support for cyclic oxidation, followed by sequential coupling with a linker and a chelating agent. The protecting group was then removed, and the crude product was cleaved from the resin and purified by Prep-HPLC to obtain the labeled precursor TZY-2603. The synthetic route is as follows: Figure 11 As shown: The specific operating steps are as follows: (1) Resin swelling: 200 mg of 2-chlorotriphenylmethyl chloride resin (CTC Resin, degree of substitution 0.5 mmol / g) was added to the reaction tube, followed by the addition of DCM (3 mL), and the reaction was carried out under nitrogen for 30 min.
[0076] (2) Deprotection: Discard the solvent, add 3 mL of piperidine / DMF mixed solution (1 / 4, v / v) and react for 5 min. Then discard the solvent and add 3 mL of piperidine / DMF mixed solution (1 / 4, v / v) again and react for 15 min.
[0077] (3) Resin cleaning: Discard the solvent and wash with DMF (3 mL × 2), DCM (3 mL × 2) and DMF (3 mL × 2) in sequence.
[0078] (4) First amino acid linkage: Fmoc-D-Cys-OH (3 eq, 103 mg), HCTU (3 eq, 124 mg) and DIPEA (10 eq, 129 mg) were added to the reaction tube in sequence, and then DMF (3 mL) was added to dissolve them. The reaction was carried out under nitrogen for 60 min.
[0079] (5) Resin cleaning: Discard the solvent and wash with DMF (3 mL × 2), DCM (3 mL × 2) and DMF (3 mL × 2) in sequence.
[0080] (6) Deprotection: Add 3 mL of piperidine / DMF mixed solution (1 / 4, v / v) and react for 5 min. Then discard the solvent and add 3 mL of piperidine / DMF mixed solution (1 / 4, v / v) again and react for 15 min.
[0081] (7) Resin cleaning: Discard the solvent and wash with DMF (3 mL × 2), DCM (3 mL × 2) and DMF (3 mL × 2) in sequence.
[0082] (8) Second amino acid linkage: Fmoc-Phe-OH (3 eq, 116 mg), HCTU (3 eq, 124 mg) and DIPEA (10 eq, 129 mg) were added to the reaction tube in sequence, and then DMF (3 mL) was added to dissolve them. Nitrogen gas was blown in for 30 min to react.
[0083] Repeat the above steps, sequentially connecting: Fmoc-Ala-OH (93 mg), Fmoc-Leu-OH (106 mg), Fmoc-Ser(tBu)-OH (115 mg), Fmoc-Gly-OH (89 mg), Fmoc-Phe-OH (116 mg), Fmoc-Ile-OH (106 mg), Fmoc-Lys(Boc)-OH (141 mg), and Fmoc-L-Cys-OH (103 mg), with each substance used in an amount of 3 eq.
[0084] (9) Oxidative cyclization: Wash the resin with DCM (2 mL × 3), then add NMP (2 mL), and adjust the pH of the solution to 7.5 with Et3N. The oxidation reaction was carried out at room temperature for 12 hours with air introduced between 9.0 and 9.0.
[0085] (10) Resin cleaning: Discard the solvent and wash with DMF (3 mL × 2), DCM (3 mL × 2) and DMF (3 mL × 2) in sequence.
[0086] (11) Connecting arm coupling: Add Fmoc sequentially to the reaction tube NH-(CH2)5-COOH (3 eq, 102 mg), HCTU (3 eq, 124 mg) and DIPEA (10 eq, 129 mg) were dissolved in DMF (3 mL) and reacted under nitrogen for 30 min.
[0087] (12) Resin cleaning: Discard the solvent and wash with DMF (3 mL × 2), DCM (3 mL × 2) and DMF (3 mL × 2) in sequence.
[0088] (13) Deprotection: Add 3 mL of piperidine / DMF mixed solution (1 / 4, v / v) and react for 5 min. Then discard the solvent and add 3 mL of piperidine / DMF mixed solution (1 / 4, v / v) again and react for 15 min.
[0089] (14) Resin cleaning: Discard the solvent and wash with DMF (3 mL × 2), DCM (3 mL × 2) and DMF (3 mL × 2) in sequence.
[0090] (15) Coupling with chelating agents: Tri-tert-butyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid [DOTA-tri(t-butyl ester)] (3 eq, 172 mg), HCTU (3 eq, 124 mg) and DIPEA (10 eq, 129 mg) were added sequentially to the reaction tube, and then DMF (3 mL) was added to dissolve them. The reaction was carried out under nitrogen for 30 min.
[0091] (16) Resin cleaning: Discard the solvent and wash with DMF (3 mL × 2), DCM (3 mL × 2) and DMF (3 mL × 2) in sequence.
[0092] (17) Peptide shearing: Add 3 mL of shearing solution (TFA / TIPS / H2O = 95 / 2.5 / 2.5, v / v / v) to the reaction tube and place it on a shaker for 2 h.
[0093] (18) Filtration: Add the shearing system to a 1 mL disposable sterile syringe stuffed with cotton and filter. Rinse the resin with an appropriate amount of TFA. Dry the filtrate with nitrogen to obtain crude peptide solid.
[0094] (19) Purification: Add 3 mL of pre-cooled diethyl ether / n-hexane mixture (1 / 1, v / v) to the above crude peptide solid and sonicate for 30 s. Then centrifuge at 1500 rpm for at least 5 min and discard the supernatant. Subsequently, blow the precipitate with nitrogen and freeze dry to obtain a white powdery labeled precursor TZY-2603.
[0095] The mass spectrum and HPLC detection chromatogram of TZY-2603 are shown below. Figure 3 (A) and Figure 3 The structure of (B) in the middle is shown below: (20) Radionuclide labeling: TZY-2603 (20 μg) was dissolved in sodium acetate solution (0.1 mol / L, 100 mL, pH 4.1), and then added 68 A GaCl3 (10 mCi) solution was incubated at 80 °C for 10 min. The solution was diluted with physiological saline and filtered through a 0.2 μm sterile filter membrane to obtain a cyclic peptide radiotracer targeting tumor HER2. 68 Ga]Ga-TZY-2603. Utilizing YMC tria C18 filter column radio HPLC analysis 68 The radiochemical purity of Ga-TZY-2603 was determined under the following analytical conditions: column: X-Bridge C18; mobile phase A: H2O (containing 0.1% TFA); mobile phase B: acetonitrile (containing 0.1% TFA); elution gradient: mobile phase B increased from 10% to 90% within 20 min; flow rate: 1.0 mL / min.
[0096] The cyclic peptide radiotracer prepared in this embodiment [ 68 Ga]Ga-TZY-2603 for Radio HPLC analysis showed the following results: 68 The radiochemical purity of Ga]TZY-2603 is greater than 95% (Table 1), and the retention time is approximately 5.65 min. Figure 3 In (C), the tracer has a molar activity greater than 74 ± 10 GBq / μmol (Table 1).
[0097] Example 4 This embodiment provides three types of cyclic peptide radiotracers. 68 Ga]Ga-TZY-2601、[ 68 Ga]Ga-TZY-2602 and [ 68 In vitro stability study of Ga]Ga-TZY-2603, results are shown in Figure 4 .
[0098] The specific method is as follows: At 37 ℃, the three prepared cyclic peptide radiotracers (approximately 7.4 MBq, 200 μCi) were incubated in 1.0 mL PBS buffer solution and 1.0 mL mouse serum for 2 h, respectively. 20 μL samples were taken at 30 min, 60 min and 120 min, respectively, and an equal volume of acetonitrile containing 0.1% TFA was added to precipitate the protein. After vortex centrifugation, the supernatant was collected and the sample was analyzed using Radio-HPLC.
[0099] like Figure 4 The results show: 68 Ga]Ga-TZY-2601、[ 68 Ga]Ga-TZY-2602 and [ 68 Ga-TZY-2603 exhibits good stability in PBS buffer solution, and [ 68 Ga]Ga-TZY-2603 showed the best stability in mouse serum, with a content greater than 85% at 2 h.
[0100] Example 5 This embodiment provides three types of cyclic peptide radiotracers. 68 Ga]Ga-TZY-2601、[ 68 Ga]Ga-TZY-2602 and [ 68 Study on the specific uptake and binding affinity of Ga]Ga-TZY-2603 with HER2-overexpressing tumor cells in vitro.
[0101] The specific method is as follows: HCC827 lung cancer cells are injected at a rate of 1 × 10⁻⁶. 5 Cells were seeded at a density of 12-well plates, and experiments were conducted after the cells reached 70%-80% confluence.
[0102] For tumor cell uptake experiments, three radiotracers (all 740 KBq / mL) from the culture medium were added to the cells and incubated at 37 °C for 5 min, 20 min, 40 min, 60 min, and 80 min. At each time point, the culture medium was discarded, and the cells were washed three times with ice-cold DPBS. Cells were lysed with 300 μL of NaOH solution (0.2 M), and the cell lysates were collected. The radioactivity count was detected using an automated gamma counter (PerkinElmer WIZARD 22480, USA). The results showed that HER2-overexpressing tumor cells exhibited good uptake capacity for all three radiotracers. Figure 5 (A) in the middle.
[0103] For binding affinity (IC) 50 The determination of ) was carried out by [ ] respectively. 68 Ga]Ga-TZY-2601、[ 68 Ga]Ga-TZY-2602 or [ 68 Ga-TZY-2603 (approximately 20 μCi / mL) was added to HCC827 cells, along with different concentrations of HER2 antibody (trastuzumab). The cells were incubated at 37 °C for 120 min. The culture medium was discarded, and the cells were washed three times with ice-cold DPBS. Cells were lysed with 300 μL of 0.2 M NaOH solution, and the cell lysates were collected. The radioactivity count was detected using an automated gamma counter (PerkinElmer WIZARD 22480, USA). The results showed that the IC50 of the three tracers was... 50 The concentrations were 2.95 μM, 2.92 μM, and 2.83 μM, respectively. (See...) Figure 5 (B) in the middle.
[0104] Example 6 This embodiment provides three types of cyclic peptide radiotracers. 68 Ga]Ga-TZY-2601、[ 68 Ga]Ga-TZY-2602 and [ 68 In vivo PET / CT imaging study of Ga]Ga-TZY-2603 in HCC827 tumor-bearing BALB / c mice.
[0105] The specific method was as follows: each tumor-bearing mouse was injected with 3.7 MBq (100 μL) via the tail vein. 68 Ga]Ga-TZY-2601、[ 68 Ga]Ga-TZY-2602 and [ 68 Ga]Ga-TZY-2603 was injected and dynamic PET / CT scans were started immediately after the injection, lasting for 60 minutes (n = 3) to analyze the uptake and metabolism of the tracer in the tumor.
[0106] PET / CT series images showed that these tracers exhibited considerable tumor uptake at 60 minutes post-injection, see [link to PET / CT series images]. Figure 6 (A) in which [ 68 Ga]Ga-TZY-2601、[ 68 Ga]Ga-TZY-2602 and [ 68 The peak uptake values of Ga-TZY-2603 at 3 minutes post-injection were 2.53 %ID / g, 2.80 %ID / g, and 3.27 %ID / g, respectively; quantitative analysis of the uptake values further indicated that... 68Ga]Ga-TZY-2601、[ 68 Ga]Ga-TZY-2602 and [ 68 The time-activity curves of Ga-TZY-2603 in the liver, heart, and kidneys were almost identical within 0 to 60 minutes after injection. Figure 6 (B) of the above; furthermore, all three radioligands were rapidly cleared from the heart within 20 minutes after injection, which means that [ 68 Ga]Ga-TZY-2601、[ 68 Ga]Ga-TZY-2602 and [ 68 The Ga-TZY-2603 provides high-contrast PET / CT images with extremely low background capture.
[0107] Example 7 This embodiment provides cyclic peptide radiotracers. 68 Ga]Ga-TZY-2603 and linear peptide radioactive tracers [ 68 Ga]Ga-DOTA-WC8 (References: Xu Guo, Chunwei Xu, Xue Zhu, et al . In silico design and evaluation of novel peptide-based PET probe for noninvasive imaging of HER2 expression in breast cancer. J. Med. Chem. , 2025, 68(10), 10461-10472.) Comparative study of in vivo PET / CT imaging in HCC827 tumor-bearing BALB / c mice.
[0108] The specific method was as follows: each tumor-bearing mouse was injected with 3.7 MBq (100 μL) via the tail vein. 68 Ga]Ga-TZY-2603 and [ 68 Ga]Ga-DOTA-WC8 was injected and dynamic PET / CT scans were started immediately after the injection, lasting for 60 minutes (n = 3) to analyze the uptake and metabolism of the tracer in the tumor.
[0109] PET / CT series images show that 30 to 60 minutes after injection, [ 68 Ga]Ga-TZY-2603 uptake at tumor sites and [ 68 Ga]Ga-DOTA-WC8 equivalent ( Figure 7 ).
[0110] Example 8 This embodiment provides cyclic peptide radiotracers. 68 In vitro biodistribution of Ga]Ga-TZY-2603 in HCC827 tumor-bearing BALB / c mice.
[0111] The specific method is as follows: [ 68 Ga-TZY-2603 was injected into BALB / c tumor-bearing mice via the tail vein. The mice were euthanized at 5 min, 20 min, 40 min and 80 min after injection. Blood, heart, liver, thymus, pancreas, spleen, kidney, lung, stomach, small intestine, muscle, bone and brain were collected and weighed. The radioactivity count was then determined using a fully automated gamma counter, and the percentage injection dose rate (%ID / g) per gram of tissue was calculated.
[0112] The results show: [ 68 Ga-TZY-2603 was largely cleared from the blood and major organs, including the heart, muscles, and bones, 60 minutes after intravenous injection; the renal radioactivity decreased from 15.01 ± 0.34 %ID / g at 5 minutes post-injection to 6.83 ± 1.21 %ID / g at 80 minutes post-injection. 68 Ga-TZY-2603 accumulation in tumors gradually increased to 2.42 ± 0.20 %ID / g within 0 min-5 min, and then began to decline; furthermore, the maximum tumor-to-organ uptake ratio was reached within 40 min-80 min, indicating that [ 68 Ga]Ga-TZY-2603 has good tumor-preserving ability ( Figure 8 ).
[0113] The above description is only a preferred embodiment of the present invention, but the scope of protection of the present invention is not limited thereto. Any equivalent substitutions or modifications made by those skilled in the art within the scope of the technology disclosed in the present invention, based on the technical solution and inventive concept of the present invention, should be covered within the scope of protection of the present invention.
Claims
1. A labeled precursor of a cyclic peptide radiotracer targeting tumor HER2, characterized in that, The labeled precursor has an ABC structure, wherein A is a chelating agent, B is a linker arm, and C is a cyclic peptide compound, with one end of the linker arm connected to the chelating agent and the other end connected to the cyclic peptide compound; The amino acid sequence of the cyclic peptide compound is shown in SEQ ID NO: 1, which is cyclo (1,10)[Cys-Lys-Ile-Phe-Gly-Ser-Leu-Ala-Phe-Cys], and the cysteine at position 1 and the cysteine at position 10 form a cyclic structure through a disulfide bond. The linker arm is -NH-(CH2)5-CO-, the amino terminus of the linker arm is connected to the chelating agent, and the carboxyl terminus of the linker arm is connected to the amino group of the N-terminal cysteine of the cyclic peptide compound. The chelating agent is 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid.
2. The labeling precursor according to claim 1, characterized in that, The cyclic peptide compound is selected from any one of (1)-(3) below: (1) The cysteine residues at the C-terminus and N-terminus of the cyclic peptide compound are both L-type; (2) The cysteine at the C-terminus of the cyclic peptide compound is of type L and the cysteine at the N-terminus is of type D; (3) The cysteine at the C-terminus of the cyclic peptide compound is of type D and the cysteine at the N-terminus is of type L.
3. The labeling precursor according to claim 1 or 2, characterized in that, The labeling precursor is one of TZY-2601, TZY-2602, or TZY-2603; wherein, when both the C-terminal and N-terminal cysteine residues in the cyclic peptide compound are L-type, the labeling precursor is TZY-2601; when the C-terminal cysteine residue in the cyclic peptide compound is L-type and the N-terminal cysteine residue is D-type, the labeling precursor is TZY-2602; and when the C-terminal cysteine residue in the cyclic peptide compound is D-type and the N-terminal cysteine residue is L-type, the labeling precursor is TZY-2603.
4. The method for preparing the labeled precursor according to any one of claims 1 to 3, characterized in that, Includes the following steps: S1, Synthesizing cyclic peptide compounds; S2. The cyclic peptide compound is coupled with a linker and a chelating agent to obtain a crude product of the labeled precursor. S3. The crude product is purified to obtain the labeled precursor.
5. The preparation method according to claim 4, characterized in that, The method for synthesizing the cyclic peptide compound in S1 includes: synthesizing a linear polypeptide having the same amino acid sequence as the cyclic peptide compound, and then oxidizing it into a cyclization by introducing air onto a solid support to obtain the cyclic peptide compound; the purification reagent in S3 is a mixture of diethyl ether and n-hexane, and the volume ratio of the diethyl ether to the n-hexane is 1:
1.
6. A cyclic peptide radiotracer targeting tumor HER2, characterized in that, The cyclic peptide radiotracer comprises a nuclide and the labeled precursor as described in any one of claims 1 to 3, wherein the structure of the cyclic peptide radiotracer is DABC, wherein D is selected from the nuclide. 68 Ga.
7. The cyclic peptide radiotracer according to claim 6, characterized in that, The cyclic peptide radiotracer is [ 68 Ga]Ga-TZY-2601、[ 68 Ga]Ga-TZY-2602 or [ 68 One of Ga]Ga-TZY-2603.
8. The method for preparing the cyclic peptide radiotracer according to claim 6, characterized in that, The preparation method includes the following steps: The labeling precursor is dissolved in a buffer solution to obtain a labeling precursor solution; wherein the buffer solution is selected from at least one of sodium acetate and phosphate buffer solution, and the pH value of the buffer solution is 4.0 to 6.0; The labeled precursor solution was mixed with a radionuclide solution and incubated to obtain a cyclic peptide radiotracer; wherein the radionuclide solution was selected from... 68 The GaCl3 solution was used for incubation under the following conditions: incubation at 80 ℃ to 100 ℃ for 5 min to 20 min.
Citation Information
Patent Citations
Novel tumor antigen cyclopeptide
CN104292308A
High-affinity HER2 targeting polycyclic peptide molecule as well as preparation method and application thereof
CN121717877A
